A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

STATUS

Recruiting
End date

Jan 28, 2026
participants needed

760
sponsor

University of Birmingham

Send

Updated on 19 February 2024

See if I qualify

remission

renal function

hla-a

myeloid leukemia

cytarabine

cell transplantation

fludarabine

busulfan

myelodysplasia

thiotepa

behavioral intervention

pulmonary function test

leukemia

blood count

complete blood count

renal function test

recurrent disease

kidney function test

secondary acute myeloid leukemia

blood cell count

consolidation therapy

secondary aml

conditioning therapy

acute myeloid leukemia

conditioning therapies

Summary

Show definitions

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. In the last decade the use of reduced intensity transplants has allowed the extension of the potentially curative effect of transplantation to older patients in whom it was previously precluded. Although a major advance such transplants are associated with a high risk of disease relapse particularly in patients with high risk disease.

This study will evaluate new transplant strategies with the aim of improving the outcome of patients with AML and high risk MDS after stem cell transplantation. Three approaches to improve transplant outcome will be studied:

Comparing the new pre-transplant consolidation therapy vyxeos with the standard consolidation therapy
Comparing new conditioning therapies in patients under the age of 55 years
Comparing new conditioning therapies in patients aged 55 and over

All patients will be followed up for a minimum of 2 years.

Description

This is a randomised, international, phase II/III, multicentre, clinical trial in patients with AML and MDS undergoing allo-SCT. Patients with AML or MDS who fulfil the eligibility criteria will be invited to participate in the trial across centers performing allo-SCT.

Patients will be randomised to treatment based on a minimisation algorithm prepared at the Cancer Research UK Clinical Trials Unit (CRCTU).

Randomisation 1 (R1) will compare the novel consolidation therapy vyxeos with the standard consolidation therapy intermediate dose cytarabine.

Randomisation 2 (R2) will compare the novel conditioning regimen thiotepa/busulphan/fludarabine (TBF) with the standard conditioning therapy fludarabine/busulphan (FB4) in patients aged under 55 years of age.

Randomisation 3 (R3) will compare the novel conditioning regimen mini thiotepa/busulphan/fludarabine (mini TBF) with the standard regimen fludarabine/busulphan (FB2) in patients aged 55 years of age and over.

Details

Condition	Preleukemia, Acute myeloid leukemia, Acute myeloid leukemia, MYELODYSPLASTIC SYNDROME
Age	18years - 100years
Treatment	Fludarabine, Vyxeos, Busulphan, Thiotepa, Cytarabine
Clinical Study Identifier	NCT04217278
Sponsor	University of Birmingham
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Eligibility Criteria for Randomisation 1 Inclusion Criteria for Randomisation 1'
	b'Patients (\\u2265 18 years old) with a morphological documented diagnosis of AML or MDS who'
	b'are deemed fit for allo-SCT with one of the following disease characteristics:'
	b'AML'
	b'o Patients in 1st complete remission (CR1) defined as < 5% blasts'
	b'Patients in 2nd complete remission (CR2) defined as < 5% blasts'
	b'Secondary AML (defined as previous history of MDS, antecedent haematological'
	b'disease or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts MDS'
	b'Patients with advanced or high risk MDS with an IPSS-R of \\u22653.5 (intermediate 3.5'
	b'or higher)'
	b'Patients with an identified HLA identical sibling or suitable matched unrelated donor'
	b'(suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C'
	b'or DR\\u03b21)'
	b'Patients must be considered suitable/fit to undergo allo-SCT as clinically judged by'
	b'the Local Investigator'
	b'Females of and male patients of reproductive potential (i.e., not post-menopausal or'
	b'urgically sterilised) must use appropriate, highly effective, contraception from the'
	b'point of commencing therapy until 6 months after treatment'
	b'Patients have given written informed consent'
	b'Patients willing and able to comply with scheduled study visits and laboratory tests'
Exclusion Criteria
	b'Patients with contraindications to receiving allo-SCT'
	b'Patients who have already received Vyxeos in their most recent treatment schedule'
	b'Female patients who are pregnant or breastfeeding. All women of childbearing potential'
	b'must have a negative pregnancy test before commencing treatment'
	b'Adults of reproductive potential not willing to use appropriate, highly effective,'
	b'contraception during the specified period'
	b'Patients with renal or hepatic impairment as clinically judged by the Local'
	b'Investigator'
	b'Patients with active infection, HIV-positive or chronic active HBV or HCV.'
	b'Patients with a prior malignancy, except lobular breast carcinoma in situ, fully'
	b'resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma'
	b'in situ. Cancer treated with curative intent \\u2265 5 years previously will be allowed.'
	b'Cancer treated with curative intent < 5 years previously will not be allowed'
	b'History of serious hypersensitivity reaction to cytarabine, daunorubicin, or any'
	b'component of the Vyxeos formulation.'
	b"Known history of Wilson's disease or other copper-related metabolic disorder since"
	b'copper gluconate is a component of the Vyxeos formulation'
	b'Eligibility Criteria for Randomisation 2 Inclusion Criteria for Randomisation 2'
	b'Patients aged between 18 - 54 years with a morphological documented diagnosis of AML'
	b'or MDS who are deemed fit for a MAC allo-SCT with one of the following disease'
	b'characteristics: AML'
	b'Patients in 1st complete remission (CR1) defined as < 5% blasts'
	b'Patients in 2nd complete remission (CR2) defined as < 5% blasts'
	b'Secondary AML (defined as previous history of MDS, antecedent haematological'
	b'disease or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts'
	b'Must have received at least two courses of prior intensive chemotherapy prior to'
	b'transplant unless there are exceptional circumstances MDS'
	b'Patients with advanced or high risk MDS (with an IPSS-R of \\u22653.5 (intermediate 3.5'
	b'or higher) who have < 10% blasts at the time of randomisation following intensive'
	b'chemotherapy (including R1 randomisation) or hypomethylating agents if necessary'
	b'Patients with an identified HLA identical sibling or suitable matched unrelated donor'
	b'(suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C'
	b'or DR\\u03b21)'
	b'Patients with an ECOG performance status of 0, 1 or 2'
	b'Patients considered suitable/fit to undergo a MAC allo-SCT as clinically judged by the'
	b'Local Investigator including:'
	b'Adequate hepatic and renal function as determined by full blood count and'
	b'biochemistry assessment'
	b'Resolution of any toxic effects of prior therapy (including radiotherapy,'
	b'chemotherapy or surgical procedures)'
	b'Performance of cardiac or pulmonary function tests (where there is a previous'
	b'history of cardiac or pulmonary impairment)'
	b'Females of and male patients of reproductive potential (i.e., not post-menopausal or'
	b'urgically sterilised) must use appropriate, highly effective, contraception from the'
	b'point of commencing therapy until 12 months after treatment'
	b'Patients have given written informed consent'
	b'Patients willing and able to comply with scheduled study visits and laboratory tests'
	b'Patients with contraindications to receiving a MAC allo-SCT 2. Female patients who are'
	b'pregnant or breastfeeding. All women of childbearing potential must have a negative'
	b'pregnancy test before commencing treatment 3. Adults of reproductive potential not willing'
	b'to use appropriate, effective, contraception during the specified period 4. Patients with'
	b'renal or hepatic impairment as clinically judged by the Local Investigator 5. Patients with'
	b'active infection, HIV-positive or chronic active HBV or HCV 6. Patients with a prior'
	b'malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous'
	b'cell carcinoma of skin or treated cervical carcinoma in situ. Cancer treated with curative'
	b'intent \\u2265 5 years previously will be allowed. Cancer treated with curative intent < 5 years'
	b'previously will not be allowed.'
	b'Eligibility Criteria for Randomisation 3 Inclusion Criteria for Randomisation 3'
	b'Patients aged between 55 years or older with a morphological documented diagnosis of'
	b'AML or MDS who are deemed fit for a RIC allo-SCT with one of the following disease'
	b'characteristics:'
	b'AML o Patients in 1st complete remission (CR1) defined as < 5% blasts'
	b'o Patients in 2nd complete remission (CR2) defined as < 5% blasts'
	b'o Secondary AML (defined as previous history of MDS, antecedent haematological disease'
	b'or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts'
	b'o Must have received at least two courses of prior intensive chemotherapy prior to'
	b'transplant unless there are exceptional circumstances MDS'
	b'Patients with advanced or high risk MDS (with an IPSS-R of \\u22653.5 (intermediate 3.5'
	b'or higher) who have < 10% blasts at the time of randomisation following intensive'
	b'chemotherapy (including R1 randomisation) or hypomethylating agents if necessary'
	b'Patients with an identified HLA identical sibling or suitable matched unrelated donor'
	b'(suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C'
	b'or DR\\u03b21)'
	b'Patients with an ECOG performance status of 0, 1 or 2'
	b'Patients considered suitable/fit to undergo a RIC allo-SCT as clinically judged by the'
	b'Local Investigator including:'
	b'Adequate hepatic and renal function as determined by full blood count and'
	b'biochemistry assessment'
	b'Resolution of any toxic effects of prior therapy (including radiotherapy,'
	b'chemotherapy or surgical procedures)'
	b'Performance of cardiac or pulmonary function tests (where there is a previous'
	b'history of cardiac or pulmonary impairment'
	b'Females of and male patients of reproductive potential (i.e., not post-menopausal or'
	b'urgically sterilised) must use appropriate, highly effective, contraception from the'
	b'point of commencing therapy until 12 months after treatment'
	b'Patients have given written informed consent'
	b'Patients willing and able to comply with scheduled study visits and laboratory tests'
	b'Patients with contraindications to receiving a RIC allo-SCT 2. Female patients who are'
	b'pregnant or breastfeeding. All women of childbearing potential must have a negative'
	b'pregnancy test before commencing treatment 3. Adults of reproductive potential not willing'
	b'to use appropriate, effective, contraception during the specified period 4. Patients with'
	b'renal or hepatic impairment as clinically judged by the Local Investigator 5. Patients with'
	b'active infection, HIV-positive or chronic active HBV or HCV 6. Patients with a prior'
	b'malignancies, except lobular breast carcinoma in situ, fully resected basal cell or'
	b'quamous cell carcinoma of skin or treated cervical carcinoma in situ. Cancer treated with'
	b'curative intent \\u2265 5 years previously will be allowed. Cancer treated with curative intent <'
	b'5 years previously will not be allowed.'

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

behavioral intervention

pulmonary function test

secondary acute myeloid leukemia

blood cell count

consolidation therapy

secondary aml

conditioning therapy

acute myeloid leukemia

conditioning therapies

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT